Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of selinexor + bortezomib + dexamethasone versus bortezomib + dexamethasone in relapsed or refractory multiple myeloma
CTR20211431Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of selinexor, bortezomib, dexamethasone in multiple myeloma (MM), sponsored by Karyopharm Therapeutics Inc.. Started Jul 2021; status: completed.
02
Drugs
selinexorbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20211431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211431.